| Feature | HSPB3 summary | Comparison / nuance | Evidence |
|---|---|---|---|
| Verified identity | Human **HSPB3** encodes **heat shock protein beta-3 (HspB3)**, a member of the **small heat shock protein (sHSP/HSPB)** family with a conserved **α-crystallin domain (ACD)**. | Matches UniProt Q12988 annotation and the human sHSP family framework. | (pqac-00000001, pqac-00000005) |
| Molecular size | HSPB3 is a **small ~17 kDa protein**; reviews list **16.97 kDa** and **150 aa**. | Smaller than many other HSPBs; classified among tissue-restricted rather than ubiquitous sHSPs. | (pqac-00000001, pqac-00000005) |
| Domain architecture | Contains the canonical **ACD** flanked by a **unique N-terminal region**; unlike several other HSPBs, HSPB3 **lacks the typical C-terminal architecture** associated with stronger oligomerization/chaperone activity. It carries an **I/V-X-I/V motif in the N-terminus**. | Reviews note that absence of the usual C-terminal motif arrangement helps explain its **low oligomerization propensity** and distinctive behavior relative to HSPB1/HSPB4/HSPB5. | (pqac-00000001, pqac-00000002, pqac-00000011) |
| Core biochemical class | HSPB3 is an **ATP-independent chaperone/holdase**. sHSPs bind non-native proteins to prevent aggregation and can pass clients to ATP-dependent systems such as **HSP70/HSP40** for refolding or routing to degradation. | This is the canonical sHSP mechanism; HSPB3 conforms to the family-level ATP-independent holdase model. | (pqac-00000001, pqac-00000005, pqac-00000011) |
| Chaperone potency / specificity | HSPB3 is generally considered to have **moderate or selective chaperone activity**, rather than the broad promiscuous anti-aggregation activity of HSPB1/HSPB4/HSPB5. | Reviews describe **HSPB1/HSPB4/HSPB5** as the most active/promiscuous sHSPs, whereas **HSPB2/HSPB3** show intermediate or more selective activity. | (pqac-00000002, pqac-00000005) |
| Primary experimentally defined substrate | The best-defined HSPB3 client is **lamin B receptor (LBR)**. HSPB3 **binds LBR in the nucleoplasm** and **maintains it in a dynamic state**, promoting proper LBR relocalization during differentiation. | This is more specific than the broad anti-aggregation role usually assigned to many sHSPs, making HSPB3 unusually specialized. | (pqac-00000003, pqac-00000007) |
| Functional consequence of LBR binding | By regulating LBR mobility/localization, HSPB3 promotes the **LBR-to-LMNA chromatin tether switch**, enabling transcription of **myogenic genes** and extracellular-matrix remodeling genes during muscle differentiation. HSPB3 loss increases LBR retention at the nuclear envelope and impairs differentiation. | This places HSPB3 in a **nuclear-envelope/chromatin-remodeling arm of myogenesis**, not just generic proteostasis. | (pqac-00000003, pqac-00000007) |
| Subcellular localization | In differentiating myoblasts, HSPB3 shows **heterogeneous localization**: **cytoplasm + nucleoplasm** in some cells, and **enrichment at the nuclear envelope (NE)** in others. It can form **nuclear filaments** and colocalizes with **lamin B1** at the NE. | Distinct from many sHSPs that are mainly cytoplasmic; HSPB3 has an unusually prominent **nuclear/NE pool**. | (pqac-00000002, pqac-00000007) |
| Nuclear localization determinant | The **N-terminal region** promotes **nuclear accumulation** and self-assembly/condensate behavior; once nuclear, the **ACD is sufficient** to help retain LBR in the nucleoplasm. | Supports a structure-function link between the unique N-terminus and HSPB3’s specialized nuclear role. | (pqac-00000007) |
| Mitochondrial localization | Unlike many other human sHSPs found in the **mitochondrial intermembrane space (IMS)**, **HSPB3 is not imported into mitochondria** under the tested conditions. | Adriaenssens et al. specifically note that **most sHSPs** enter the IMS, but **HSPB3** is an exception. | (pqac-00000004) |
| HSPB2-HSPB3 complex formation | HSPB3 forms a characteristic **hetero-oligomeric complex with HSPB2**, classically a **heterotetramer with a 3:1 HSPB2:HSPB3 ratio**; higher assemblies maintaining this stoichiometry have also been reported. | This is one of the best-defined specific pairings among human sHSPs and distinguishes HSPB3 from broadly self-oligomerizing family members. | (pqac-00000012, pqac-00000013) |
| Structural basis of HSPB2-HSPB3 assembly | The HSPB2/HSPB3 heteromer is assembled through the **ACDs** plus flexible **terminal-region “nuts and bolts”** involving **IXI/V motif-pocket interactions**; the full-length structure reveals a **plastic heterotetrameric assembly**. | Structural plasticity is thought to underlie sHSP cytoprotective function more generally; for HSPB3 it likely contributes to client handling and localization control. | (pqac-00000013) |
| Relationship to BAG3 pathway | In mammalian cells, **HSPB2** binds **BAG3** weakly, but **HSPB3 negatively regulates HSPB2–BAG3 association**; in human myoblasts BAG3 preferentially interacts with **HSPB8**, not HSPB3. | Suggests HSPB3 is **not a primary BAG3-associated sHSP**, unlike HSPB8, reinforcing functional specialization. | (pqac-00000012) |
| Tissue expression pattern | HSPB3 expression is **restricted / tissue-biased**, with highest expression in **skeletal muscle**; it is also reported in **cardiac muscle**, **differentiating myoblasts**, **motoneurons**, **fetal brain**, and muscle-rich tissues. It is absent from cycling myoblasts and induced upon differentiation. | In contrast, **HSPB1/HSPB5/HSPB8** are more widely expressed and stress responsive. | (pqac-00000002, pqac-00000005, pqac-00000012) |
| Developmental regulation | HSPB3 is **developmentally regulated** rather than classically heat-shock induced. During myogenesis it is **upregulated by MYOD**; MYOD occupancy and activating chromatin marks at HSPB3 regulatory regions increase in differentiated muscle cells. | Reviews note **HSPB3 does not respond strongly to heat shock**, unlike several canonical stress-inducible sHSPs. | (pqac-00000002, pqac-00000003, pqac-00000008) |
| Role in myogenesis | HSPB3 is **pro-myogenic**: depletion blocks differentiation and lowers **MYOG** expression, whereas overexpression is sufficient to promote differentiation in human myoblasts and even **rhabdomyosarcoma** cells. | This is one of the clearest functional assignments for HSPB3 in human cells. | (pqac-00000003, pqac-00000007) |
| Disease-linked variants | Disease-associated missense variants include **R7S** and **R116P**. R116P forms **nuclear aggregates**, immobilizes LBR, fails to drive myogenic differentiation, and activates the **unfolded protein response**. | Links HSPB3 dysfunction to **neuromuscular disease/myopathy** through loss of its specialized nuclear chaperone function rather than only general proteostasis failure. | (pqac-00000003, pqac-00000005, pqac-00000010) |
| Overall functional interpretation | HSPB3 is best understood as a **specialized, muscle-enriched nuclear sHSP chaperone** that couples **proteostasis-like client handling** to **nuclear-envelope remodeling and transcriptional reprogramming during muscle differentiation**. | This differentiates HSPB3 from broadly stress-protective sHSPs and explains why its disease phenotypes are strongly neuromuscular. | (pqac-00000003, pqac-00000004, pqac-00000005, pqac-00000006) |


*Table: This table summarizes the key molecular, structural, regulatory, localization, and functional properties of human HSPB3, including its specialized interaction with LBR and hetero-oligomerization with HSPB2. It is useful for quickly distinguishing HSPB3 from more canonical, broadly stress-inducible small heat shock proteins.*